**Formulation and *in vitro* characterization of tapentadol HCL as immediate release tablets**

Suresh Kumar Paramasivam *, Priyanka Batlanki, Sindhu Vemula, Jagannath Patro Varanasi, Praveen Kumar T and Yasmin Sulthana Syed

*Department of Pharmaceutics, Browns College of Pharmacy, Khammam, Telangana, India.*

Publication history: Received on 27 July 2018; revised on 21 August 2018; accepted on 29 August 2018

**Article DOI:** [https://doi.org/10.30574/gscbps.2018.4.3.0072](https://doi.org/10.30574/gscbps.2018.4.3.0072)

**Abstract**

The aim of the present study is to develop and evaluate the immediate release tablet of tapentadol by direct compression method. The superdisintegrant explotab, solutab and polyplasdoneXL were used for immediate release of drug from tablet. The prepared tablets were evaluated for all pre-compression parameters and post-compression parameters. The drug-excipients interaction was investigated by FTIR. All formulation showed compliances with Pharmacopoeial standards. The study reveals that formulations prepared by direct compression F2 exhibits highest dissolution using explotab showed faster drug release 95.48 % over the period of 45 min while disintegration time of the tablet was showed 12 sec in comparison to other formulations of tapentadol.

**Keywords:** Immediate release; Explotab; Solutab; Polyplasdone XL

**1. Introduction**

An immediate release dosage form allows a manufacturer to extend market exclusivity while offering patients a convenient dosage form or dosage regimen. Immediate Release Tablets are those tablets which are designed to disintegrate and release their medication with no special rate controlling features such as special coatings and other techniques [1, 2] immediate releases and fast dispersing drug delivery system may offer a solution to these problems. Recently, immediate release tablets have started gaining popularity and acceptance as a drug delivery system, mainly because they are easy to administer, has quick onset of action is economical and lead to better patient compliance. They are also a tool for expanding markets, extending product life cycles and generating opportunities. [3, 4].

Immediate release tablets are those which disintegrate rapidly and get dissolved to release the medicaments. Immediate release may be provided by way of an appropriate pharmaceutically acceptable diluent or carrier, which diluent or carrier does not prolong to an appreciable extent, the rate of drug release and/or absorption. This term excludes formulations which are adapted to provide for “modified”, “controlled”, “sustained”, “prolonged”, “extended” or “delayed” release of drug [5, 6].

The immediate-release formulation of Tapentadol is indicated for the relief of moderate to severe acute pain. The long-acting formulation serves as a continuous, around-the-clock analgesic that is indicated for the relief of moderate to severe chronic pain or neuropathic pain associated with diabetic peripheral neuropathy [7]. The main objective of this work was to investigate the possibility of obtaining an immediate release formulation of Tapentadol by using different polymer ratios. The various physicochemical characteristics and the *in –vitro* release rates from these study.

*Corresponding author
E-mail address: surae81@gmail.com

Copyright © 2018 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution License 4.0.
2. Material and methods

2.1. Materials

Tapentadol powder was kindly provided by Aurobindo Pharmaceutical (Hyderabad). All other excipients and materials used during the experiment are LR grade or the best possible pharma grades available were used as supplied by the manufacturer.

2.2. Pre formulation studies

Pre formulation involves the application of biopharmaceutical principles to the physicochemical parameters of drug substance are characterized with the goal of designing optimum drug delivery system [8].

2.3. Drug-excipients compatibility studies

Drug excipients compatibility studies were carried out by mixing the drug with various excipients in different proportions (in 1:1 ratio were prepared to have maximum likelihood interaction between them) was placed in a vial, and closed with rubber stopper and sealed properly [9].

2.4. Formulation of tapentadol immediate release tablet

Drug and different concentrations for super Disintegrates and required ingredients were accurately weighed and passed through a 40-mesh screen to get uniform size particles and mixed in a glass mortar for 15 minutes. The obtained blend was lubricated with Magnesium stearate and glidant (Talc) was added and mixing was continued for further 5 minutes. The resultant mixture was directly compressed into tablets by using punch of rotary tablet compression machine. Compression force was kept constant for all formulations [10].

Table 1 Formulation of immediate release tablets

<table>
<thead>
<tr>
<th>Ingredients (mg)</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
<th>F5</th>
<th>F6</th>
<th>F7</th>
<th>F8</th>
<th>F9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tapentadol</td>
<td>120</td>
<td>120</td>
<td>120</td>
<td>120</td>
<td>120</td>
<td>120</td>
<td>120</td>
<td>120</td>
<td>120</td>
</tr>
<tr>
<td>Explotab</td>
<td>40</td>
<td>80</td>
<td>120</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Solutab</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>40</td>
<td>80</td>
<td>120</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Polyplesadone XL</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>40</td>
<td>80</td>
<td>120</td>
</tr>
<tr>
<td>Sodium stearyl fumerate</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Talc</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Menthol</td>
<td>1.5</td>
<td>1.5</td>
<td>1.5</td>
<td>1.5</td>
<td>1.5</td>
<td>1.5</td>
<td>1.5</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>MCC</td>
<td>134.5</td>
<td>94.5</td>
<td>54.5</td>
<td>134.5</td>
<td>94.5</td>
<td>54.5</td>
<td>134.5</td>
<td>594.5</td>
<td>94.5</td>
</tr>
<tr>
<td>Total weight of tablets</td>
<td>300</td>
<td>300</td>
<td>300</td>
<td>300</td>
<td>300</td>
<td>300</td>
<td>300</td>
<td>300</td>
<td>300</td>
</tr>
</tbody>
</table>

2.5. Quality control study of the prepared tablets

The prepared tablets from each formulation were subjected to the tablets quality control tests as drug content, weight uniformity, tablets thickness, disintegration time, hardness and friability [11].

2.5.1. Thickness

The thickness of tablets was determined by using Digital micrometer. Ten individual tablets from each batch were used and the results averaged.

2.5.2. Weight variation

Twenty tablets randomly selected from each batch and individually. Weighed. The average weight and standard deviation three batches were calculated. It passes the test weight variation test if not more than two of the individual tablets weights deviate from the average weight by more than the allowed percentage deviation and more deviate by more than twice the percentage shown. It was calculated on an electronic weighing balance [12].
2.5.3. Friability

The friability values of the tablets were determined using a Roche-type friabilator. Accurately weighed six tablets were placed in Roche friabilator and rotated at 25 rpm for 4 min [13]. Percentage friability was calculated using the following equation.

\[ 	ext{Friability} = \frac{w_0 - w}{w_0} \times 100 \]

2.5.4. Drug content

The content of drug was carried out by five randomly selected tablets of each formulation. The five tablets were ground in mortar to get powder, this powder was dissolved in pH 6.8 phosphate buffer by sonication for 30 min and filtered through filter paper. The drug content was analyzed spectrophotometrically at 275 nm using UV spectrophotometer. Each measurement was carried out in triplicate and the average drug content was calculated.

2.5.5. Disintegration test

Six tablets were taken randomly from each batch and placed in USP disintegration apparatus baskets. Apparatus was run for 10 minutes and the basket was lifted from the fluid, observe whether all of the tablets have disintegrated [14].

2.5.6. Dissolution test of tapentadol HCL tablets

Drug release from Tapentadol HCL tablets was determined by using dissolution test United States Pharmacopoeia (USP) 24 type II (paddle). The parameters used for performing the dissolution were pH 6.8 phosphate buffer as the dissolution medium of quantity 500 ml. The whole study is being carried out at a temperature of 37 °C and at speed of 50 rpm [15].

The 5 ml aliquots of dissolution media were withdrawn each time at suitable time intervals (5, 10, 15, 20, 25 and 30 minutes.) and replaced with fresh medium. After withdrawing, samples were filtered and analyzed after appropriate dilution by UV Spectrophotometer. The concentration was calculated using standard calibration curve.

3. Results and discussion

3.1. Characterization of precompression blend

The precompression blend of tapentadol HCL were characterized with respect to angle of repose, bulk density, tapped density, Carr's index and Hausner's ratio. Angle of repose was less than 28°, Carr’s index values were less than 11 for the precompression blend of all the batches indicating good to fair floability and compressibility. Hausner's ratio was less than 1.25 of all batches indicating good flow properties.

Table 2 Physical properties of precompression blend

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Angle of repose (θ) (°)</th>
<th>Bulk density (gm/cm³)</th>
<th>Tapped density (gm/cm³)</th>
<th>Carr’s index (%)</th>
<th>Hausner’s ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>25.10±1.18</td>
<td>0.53±0.02</td>
<td>0.59±0.03</td>
<td>9.43±2.82</td>
<td>1.11±0.15</td>
</tr>
<tr>
<td>F2</td>
<td>25.43±1.37</td>
<td>0.54±0.01</td>
<td>0.60±0.01</td>
<td>9.40±2.85</td>
<td>1.10±0.04</td>
</tr>
<tr>
<td>F3</td>
<td>25.41±2.12</td>
<td>0.54±0.04</td>
<td>0.58±0.04</td>
<td>10.01±2.22</td>
<td>1.07±0.07</td>
</tr>
<tr>
<td>F4</td>
<td>26.40±0.53</td>
<td>0.51±0.06</td>
<td>0.61±0.07</td>
<td>10.11±1.14</td>
<td>1.19±0.03</td>
</tr>
<tr>
<td>F5</td>
<td>27.12±0.83</td>
<td>0.58±0.07</td>
<td>0.63±0.09</td>
<td>10.34±3.21</td>
<td>1.08±0.01</td>
</tr>
<tr>
<td>F6</td>
<td>25.31±0.91</td>
<td>0.59±0.09</td>
<td>0.64±0.01</td>
<td>10.12±0.27</td>
<td>1.08±0.03</td>
</tr>
<tr>
<td>F7</td>
<td>26.11±1.07</td>
<td>0.56±0.05</td>
<td>0.63±0.02</td>
<td>9.93±3.94</td>
<td>1.12±0.05</td>
</tr>
<tr>
<td>F8</td>
<td>26.15±0.62</td>
<td>0.53±0.04</td>
<td>0.58±0.03</td>
<td>10.13±1.29</td>
<td>1.09±0.08</td>
</tr>
<tr>
<td>F9</td>
<td>26.10±0.83</td>
<td>0.54±0.02</td>
<td>0.61±0.08</td>
<td>10.2±1.37</td>
<td>1.12±0.09</td>
</tr>
</tbody>
</table>
3.2. Drug-excipient compatibility studies by FTIR studies

Tapentadol HCL was mixed with various proportions of excipients showed no colour change at the end of two months, providing no drug–excipient interactions.

Figure 1 FTIR spectra of pure drug

Figure 2 FTIR spectra of optimized formulation
3.3. Evaluation of tablets

The results of the weight variation, hardness, thickness, friability, and drug content of tablets are given in table. All the tablets of different batches complied with the official requirement of weight variation as their weight variation passes the limit. The hardness of the tablets ranged from 4.6-5 kg/cm² and the friability values were < than 0.561 % indicating that the tablets were compact and hard. The thickness of the tablets ranged from 4.71-4.91 cm. All the formulations satisfied the content of the drug as they contained 98-100% of Tapentadol HCL and good uniformity in drug content was observed. Thus all physical attributes of the prepared tablets were found to be practically within control limits.

Table 3 Physical evaluation of tapentadol HCL

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Average Weight (mg)</th>
<th>Thickness (cm)</th>
<th>Hardness (Kg/cm²)</th>
<th>Friability (%)</th>
<th>Content uniformity (%)</th>
<th>In Vitro Disintegration time (Seconds)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>300.4±0.2</td>
<td>4.76±0.64</td>
<td>2.5±0.5</td>
<td>0.420±0.02</td>
<td>99.12</td>
<td>19</td>
</tr>
<tr>
<td>F2</td>
<td>299.9±0.1</td>
<td>4.74±0.57</td>
<td>2.2±0.3</td>
<td>0.341±0.01</td>
<td>99.03</td>
<td>12</td>
</tr>
<tr>
<td>F3</td>
<td>301.5±0.5</td>
<td>4.71±0.80</td>
<td>2.1±0.1</td>
<td>0.363±0.05</td>
<td>99.98</td>
<td>24</td>
</tr>
<tr>
<td>F4</td>
<td>299.7±0.3</td>
<td>4.80±0.68</td>
<td>2.1±0.8</td>
<td>0.561±0.07</td>
<td>99.87</td>
<td>26</td>
</tr>
<tr>
<td>F5</td>
<td>300.9±0.1</td>
<td>4.81±0.46</td>
<td>2.0±0.2</td>
<td>0.482±0.09</td>
<td>99.63</td>
<td>17</td>
</tr>
<tr>
<td>F6</td>
<td>300.2±0.8</td>
<td>4.74±0.57</td>
<td>2.2±0.7</td>
<td>0.513±0.05</td>
<td>99.41</td>
<td>15</td>
</tr>
<tr>
<td>F7</td>
<td>299.1±0.9</td>
<td>4.76±1.06</td>
<td>2.2±0.1</td>
<td>0.412±0.04</td>
<td>97.94</td>
<td>23</td>
</tr>
<tr>
<td>F8</td>
<td>301.4±0.5</td>
<td>4.71±0.64</td>
<td>2.3±0.2</td>
<td>0.432±0.03</td>
<td>96.16</td>
<td>16</td>
</tr>
<tr>
<td>F9</td>
<td>298.9±0.2</td>
<td>4.73±1.15</td>
<td>2.5±0.1</td>
<td>0.512±0.01</td>
<td>98.67</td>
<td>14</td>
</tr>
</tbody>
</table>

3.4. In vitro release studies

The drug release rate from tablets was studied using the USP type II dissolution test apparatus. The dissolution medium was 500 ml of pH 6.8 phosphate buffer at 50 rpm at a temperature of 37±0.5 °C. Samples of 5 ml were collected at different time intervals up to 45 min and has analyzed after appropriate dilution by using UV spectrophotometer at 275 nm.

Figure 3 In vitro dissolution data for formulation F1-F3

Among all the formulations F2 formulation containing drug and explotab showed good result that is 95.48% in 45 minutes, at the concentration of 80 mg. Hence from all the formulations it is evident that F2 formulation is the better formulation.
4. Conclusion

The formulation of immediate release tablets of tapentadol hydrochloride were prepared by direct compression method by using different ratios of superdisintegrant explotab, solutab and polyplasdone XL. Among all the formulations, the formulation F2 exhibits highest dissolution using explotab, faster drug release 95.48 % over the period of 45 min while disintegration time of the tablet was showed 12 sec. Therefore the prepared formulation of tapentadol hydrochloride containing explotab is best formulation and could be used for industrial application.

Compliance with ethical standards

Acknowledgments

With deep gratitude, I would like to thank the management, Browns College of Pharmacy for providing all the necessary facilities in the college campus to carry out research work.

Disclosure of conflict of interest

The author declare that there is no conflict of interest.
References


How to cite this article